As reported, mTOR and its downstream effectors, eIF-4E, 4EBP1, S6K1, and S6 are all biomarkers for diagnosis and prognosis in head and neck cancer, demonstrating the promising prospect for mTOR inhibitors in HNSCC treatments [268]. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.